Mission Therapeutics
CompanyUnited KingdomFounded 2011
Mission Therapeutics develops 2 assets, the furthest in phase 2 (MTX652 in acute kidney injury). Mostly small molecule acting on autophagy, USP30 and Mitochondrial biogenesis (PGC-1α); based in the United Kingdom, founded in 2011.
- 2
- Assets
- Furthest stage
- Phase 2
- Raised
- £39.5m + US$13.3m
- 1
- Trial
- 0
- Signals
Pipeline
2Inhibits USP30 to promote mitophagy.
Phase 2, Small molecule, Autophagy, USP30, acute kidney injury, heart Failure/HFpEF
Inhibits USP30 to promote mitophagy.
Phase 1, Small molecule, Mitochondrial biogenesis (PGC-1α), Autophagy, early stage Parkinson's disease, mild to moderate Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials1
- Funding rounds and grants17
- People12
- Signals2
- Similar companies6